Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.
Barbara A KonkleJohannes OldenburgJohn PasiRoshni KulkarniBeatrice NolanJohnny MahlanguGuy YoungSimon A BrownIngrid PabingerAmy ShapiroClaude NégrierVictor BlanchetteMargaret V RagniJennifer DumontStefan LethagenPublished in: Research and practice in thrombosis and haemostasis (2023)
Previously treated subjects of all ages receiving long-term prophylaxis with rFVIIIFc had sustained clinical benefits, including improved joint health and low ABR.